Multiple Technology Appraisal
Dasatinib, nilotinib and standard-dose imatinib for the first line treatment of chronic myeloid leukaemia (incl part-review of TA 70)
The FAD (final appraisal determination) will be released to consultees and commentators during next week......the week commencing Monday 12 March 2012.
It will then be published on the NICE website 5 working days after consultees have been informed.
It has been a long time for us all to wait and although CMLSg are consultees, we are still not sure what the resulting FAD will say. However, we remain hopeful that our hard work will pay off and both nilotinib and dasatinib will be available via the NHS for 1st line therapy in CP CML.
This depends on whether a PAS has been offered by both companies.
Best..... Sandy